ANI Pharmaceuticals ANIP Increase Decrease, Accrued Government Rebates
Increase Decrease, Accrued Government Rebates at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:IncreaseDecreaseAccruedGovernmentRebates.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's increase decrease, accrued government rebates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's increase decrease, accrued government rebates?
- ANI Pharmaceuticals (ANIP) reported increase decrease, accrued government rebates of -$4.74M in Q1 2026.
- How has ANI Pharmaceuticals's increase decrease, accrued government rebates changed year-over-year?
- ANI Pharmaceuticals's increase decrease, accrued government rebates decreased by 220.5% year-over-year, from $3.93M to -$4.74M.
- What is the long-term trend for ANI Pharmaceuticals's increase decrease, accrued government rebates?
- Over 2 years (2021 to 2025), ANI Pharmaceuticals's increase decrease, accrued government rebates has grown at a 181.8% compound annual growth rate (CAGR), from -$3.08M to $24.44M.
- What does increase decrease, accrued government rebates mean?
- Represents the net change in estimated liabilities for rebates owed to government health programs based on product sales. This reflects the company's exposure to regulatory pricing structures and the timing of settlement for mandatory pharmaceutical rebate programs. It is a vital metric for understanding net revenue realization and regulatory risk.